BidaskClub upgraded shares of Myokardia (NASDAQ:MYOK) from a sell rating to a hold rating in a research report released on Tuesday morning.

A number of other equities research analysts have also recently issued reports on the company. J P Morgan Chase & Co assumed coverage on Myokardia in a research note on Tuesday. They set an overweight rating and a $54.00 price objective on the stock. ValuEngine cut Myokardia from a hold rating to a sell rating in a research note on Friday, December 1st. TheStreet cut Myokardia from a c rating to a d+ rating in a research note on Friday, November 3rd. Zacks Investment Research upgraded Myokardia from a sell rating to a hold rating in a research note on Tuesday, October 17th. Finally, Wedbush restated an outperform rating and issued a $51.00 price target on shares of Myokardia in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Myokardia has an average rating of Buy and an average price target of $54.83.

Shares of Myokardia (MYOK) traded up $1.35 during trading on Tuesday, hitting $38.60. The stock had a trading volume of 487,700 shares, compared to its average volume of 323,906. Myokardia has a one year low of $10.55 and a one year high of $49.55.

Myokardia (NASDAQ:MYOK) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to analysts’ expectations of $6.10 million. During the same quarter in the prior year, the business posted ($0.35) EPS. The business’s revenue was up 58.6% compared to the same quarter last year. research analysts forecast that Myokardia will post -1.62 earnings per share for the current year.

In other Myokardia news, major shareholder Rock Ventures Ii L.P. Third sold 201,400 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $43.00, for a total transaction of $8,660,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Anastasios Gianakakos sold 4,300 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $40.86, for a total value of $175,698.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,286,713 shares of company stock worth $55,102,695. 33.40% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of MYOK. Vanguard Group Inc. increased its position in Myokardia by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 686,119 shares of the biotechnology company’s stock worth $9,022,000 after buying an additional 55,927 shares during the period. Geode Capital Management LLC grew its holdings in shares of Myokardia by 10.7% during the 1st quarter. Geode Capital Management LLC now owns 134,730 shares of the biotechnology company’s stock worth $1,771,000 after purchasing an additional 13,057 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Myokardia by 5.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 2,394 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Myokardia by 260.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 56,400 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 40,744 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Myokardia by 45.4% during the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 5,773 shares in the last quarter. Hedge funds and other institutional investors own 63.61% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Myokardia (MYOK) Raised to Hold at BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/myokardia-myok-raised-to-hold-at-bidaskclub/1766366.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Analyst Recommendations for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with Analyst Ratings Network's FREE daily email newsletter.